

8 July 2010

**FuturaGene plc ("FuturaGene" or "the Company")**

Announcement of Court sanction of Scheme of Arrangement, issue of ordinary shares and directors' shareholdings

Further to the announcement on 21 June 2010 in relation to the results of the Court Meeting and General Meeting, FuturaGene is pleased to announce that the Court has today sanctioned the Scheme in connection with the recommended all cash offer for the Company by Suzano Trading Limited a wholly owned subsidiary of Suzano Papel e Celulose S.A..

The Scheme remains conditional upon the Court confirming the Reduction of Capital at the Reduction Court Hearing which is scheduled for 12 July 2010 and the Reduction Court Order and Statement of Capital as approved by the Court being delivered to and registered by the Registrar of Companies .

The last day for dealings in and for registration of transfers of FuturaGene Shares will be 9 July 2010. FuturaGene Shares will be suspended from trading on AIM with effect from 7:00 a.m. on 12 July 2010 and, subject to confirmation of the Reduction of Capital by the Court on 12 July 2010 and the Reduction Court Order, together with the Statement of Capital, being duly registered, trading in FuturaGene Shares on AIM will be cancelled with effect from 7.00 a.m. on 13 July 2010.

The Company has today issued a total of 820,000 FuturaGene Shares following exercise of FuturaGene Share Options. The interests of the FuturaGene Directors who have exercised FuturaGene Share Options, immediately prior to, and following the issue of such FuturaGene Shares are as follows:

Director	Number of FuturaGene Shares prior to exercise of FuturaGene Share Options	Number of FuturaGene Shares issued following exercise of FuturaGene Share Options	Percentage of enlarged share capital following issue of FuturaGene Shares
Dr. Stanley Hirsch	1,070,034*	250,000	2.21%
Dr. Ziv Shani	62,694**	400,000	0.77%

\* Includes 1,065,751 FuturaGene Shares registered in the name of Ya'acov Messing in trust for Dr. Hirsch

\*\* Registered in the name of Ya'acov Messing in trust for Dr. Shani.

Application has been made for these shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings will commence at 8.00am on 13 July 2010. However, if as scheduled, the Scheme becomes effective on 13 July 2010 these shares will be cancelled in accordance with the Scheme and accordingly will not be admitted to trading.

Following the issue of the 820,000 FuturaGene Shares, the Company's issued share capital consists of 59,792,239 FuturaGene Shares. This figure of 59,792,239 FuturaGene Shares may be used by shareholders in the Company as the denominator for the calculations by which they determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company.

Terms defined in the scheme document sent to FuturaGene Shareholders on 28 May 2010 (the "Scheme Document") have the same meanings in this announcement.



All references to times in this announcement are to London times unless otherwise stated.

For further information, please contact:

**FuturaGene Plc**

Dr. Nissim Chen +972-8-9319550

**Israel Office:** 2 Pekeris St., Park Tamar, PO Box 199, Rehovot 76100 Israel. T+972-8-9319550; F +972-8-9319515 [www.futuragene.com](http://www.futuragene.com)